Literature DB >> 12393671

Mural thrombus generation in type 2A and 2B von Willebrand disease under flow conditions.

Mitsuhiko Sugimoto1, Hideto Matsui, Tomohiro Mizuno, Shizuko Tsuji, Shigeki Miyata, Masanori Matsumoto, Michio Matsuda, Yoshihiro Fujimura, Akira Yoshioka.   

Abstract

To explore the mechanisms that underlie the bleeding tendency in type 2A and 2B von Willebrand disease (VWD), we analyzed the mural thrombus generation process on a collagen surface under physiologic blood flow in a perfusion chamber using whole blood from these VWD patients. At a low shear rate (50 s(-1)), thrombus generation in all type 2A and 2B VWD patients was comparable to that of healthy controls. At a high shear rate (1500 s(-1)), thrombus generation was impaired in all type 2A patients, whereas that in type 2B VWD patients varied from normal to significantly defective, as judged by epifluorescence microscopy of thrombus surface coverage. However, in type 2B patients who showed normal thrombus generation at 1500 s(-1), the height and volume of thrombi was significantly reduced, albeit with the normal surface coverage, compared with control thrombi, and von Willebrand factor (VWF) was poorly distributed within the type 2B thrombus mass when analyzed in detail by confocal laser scanning microscopy. Addition of purified VWF to patient blood completely reversed the defective spatial thrombus growth in type 2B VWD. Thus, our results confirm the impaired thrombus generation in type 2B VWD, which has never been demonstrable in previous in vitro soluble-phase platelet aggregation assays, and point to the critical function of larger VWF multimers in the proper spatial growth of mural thrombi under high shear rate conditions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393671     DOI: 10.1182/blood-2002-03-0944

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

Review 1.  Flow chamber and microfluidic approaches for measuring thrombus formation in genetic bleeding disorders.

Authors:  Rogier M Schoeman; Marcus Lehmann; Keith B Neeves
Journal:  Platelets       Date:  2017-05-22       Impact factor: 3.862

2.  Use of a microchip flow-chamber system as a screening test for platelet storage pool disease.

Authors:  Hiroaki Minami; Keiji Nogami; Kenichi Ogiwara; Shoko Furukawa; Kazuya Hosokawa; Midori Shima
Journal:  Int J Hematol       Date:  2015-06-14       Impact factor: 2.490

Review 3.  Application of microfluidic devices in studies of thrombosis and hemostasis.

Authors:  Changjie Zhang; Sriram Neelamegham
Journal:  Platelets       Date:  2017-06-05       Impact factor: 3.862

4.  Functional characterization of tissue factor in von Willebrand factor-dependent thrombus formation under whole blood flow conditions.

Authors:  Yasunori Matsunari; Mitsuhiko Sugimoto; Masaaki Doi; Hideto Matsui; Masahiko Kawaguchi
Journal:  Int J Hematol       Date:  2016-08-25       Impact factor: 2.490

5.  Evaluation of clinical severity in patients with type 2N von Willebrand disease using microchip-based flow-chamber system.

Authors:  Yuto Nakajima; Keiji Nogami; Koji Yada; Takeshi Kawamura; Kenichi Ogiwara; Shoko Furukawa; Naruto Shimonishi; Masahiro Takeyama; Midori Shima
Journal:  Int J Hematol       Date:  2019-11-18       Impact factor: 2.490

6.  Intractable bleeding tendency due to acquired von Willebrand syndrome after Jarvik 2000 implant.

Authors:  Ko Sakatsume; Masatoshi Akiyama; Kenki Saito; Shunsuke Kawamoto; Hisanori Horiuchi; Yoshikatsu Saiki
Journal:  J Artif Organs       Date:  2016-03-28       Impact factor: 1.731

7.  Evaluation of a microfluidic flow assay to screen for von Willebrand disease and low von Willebrand factor levels.

Authors:  M Lehmann; K Ashworth; M Manco-Johnson; J Di Paola; K B Neeves; C J Ng
Journal:  J Thromb Haemost       Date:  2017-11-23       Impact factor: 5.824

8.  von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin αIIbβ3.

Authors:  Caterina Casari; Eliane Berrou; Marilyne Lebret; Frédéric Adam; Alexandre Kauskot; Régis Bobe; Céline Desconclois; Edith Fressinaud; Olivier D Christophe; Peter J Lenting; Jean-Philippe Rosa; Cécile V Denis; Marijke Bryckaert
Journal:  J Clin Invest       Date:  2013-11-25       Impact factor: 14.808

Review 9.  Microfluidic technology as an emerging clinical tool to evaluate thrombosis and hemostasis.

Authors:  Brian R Branchford; Christopher J Ng; Keith B Neeves; Jorge Di Paola
Journal:  Thromb Res       Date:  2015-05-21       Impact factor: 3.944

Review 10.  Of von Willebrand factor and platelets.

Authors:  Marijke Bryckaert; Jean-Philippe Rosa; Cécile V Denis; Peter J Lenting
Journal:  Cell Mol Life Sci       Date:  2014-10-09       Impact factor: 9.261

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.